GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

AstraZeneca to Pay up to $120M for Regeneron’s Mab Discovery Platform

  • AstraZeneca will utilize Regeneron’s VelocImmune® technology in its internal research programs to discover human Mabs. AstraZeneca will conduct the work at Cambridge Antibody Technology (CAT) in the U.K. as part of its recently stated aim of building a biopharmaceutical capability.

    Under the nonexclusive license agreement, AstraZeneca will pay $20 million upfront and will make up to five additional annual payments of $20 million. It retains the ability to terminate the transaction after making the first three annual payments. Upon commercialization of any antibody products discovered utilizing VelocImmune, AstraZeneca will pay Regeneron a mid-single-digit royalty on product sales.

    The VelocImmune platform generates fully human Mabs to address clinically relevant targets of therapeutic interest. Regeneron says the VelocImmune mouse mounts a robust immune response that is virtually indistinguishable from that of a wild type mouse, resulting in a reliable platform for discovering fully human Mabs.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?